Crossmark

Meaningful change threshold estimation for the non-small cell lung cancer symptom assessment questionnaire (NSCLC-SAQ): psychometric analysis from a phase 3 trial (LIBRETTO-431)

Crossref DOI link: https://doi.org/10.1007/s11136-025-03895-1

Published Online: 2025-01-23

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Clarke, Nathan

Worthy, Gill

Payakachat, Nalin

Gilligan, Adrienne M.

Cocks, Kim
Funding

Funding for this research was provided by:

Eli Lilly and Company (Not applicable)
License Information

Text and Data Mining valid from 2025-01-23

Version of Record valid from 2025-01-23
More Information

Article History

Accepted: 8 January 2025

First Online: 23 January 2025

Declarations

:

: The study was conducted in accordance with Good Clinical Practice and all study materials were approved by the appropriate ethics body at each participating site.

: For investigations involving human subjects, Informed consent has been obtained from the participants involved.

: The manuscript does not contain any individual person’s data in any form. Therefore, consent for publication was not required.

: Nalin Payakachat and Adrienne M. Gilligan are employees and minor shareholders of Eli Lilly and Company. Nathan Clarke, Gill Worthy and Kim Cocks are employees of Adelphi Values, which was contracted by Eli Lilly and Company to conduct this study.

Document is current

Any future updates will be listed below